B. Carter

发表

Adeno-associated virus vectors for gene therapy.

T. Flotte, B. Carter, 1995, Gene therapy.

Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector.

T. Flotte, S. McGrath, W. Guggino, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway.

Huidong Shi, C. Caldwell, J. Engelhardt, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Gene Delivery Technology: Adeno- Associated Virus

B. Carter, 2003 .

Adeno-associated virus Rep protein inhibits human immunodeficiency virus type 1 production in human cells

J. Trempe, B. Carter, N. Chejanovsky, 1991, Journal of virology.

Regulation of adeno-associated virus gene expression in 293 cells: control of mRNA abundance and translation

J. Trempe, B. Carter, 1988, Journal of virology.

Viral Vectors for Gene Therapy

B. Carter, 2001 .

Inhibition of cellular transformation by the adeno-associated virus rep gene.

J. Trempe, B. Carter, S. Khleif, 1991, Virology.

Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective.

B. Carter, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Analysis of adeno-associated virus (AAV) wild-type and mutant Rep proteins for their abilities to negatively regulate AAV p5 and p19 mRNA levels

M. Weitzman, B. Carter, N. Chejanovsky, 1994, Journal of virology.

6 Adeno-Associated Viral Vectors

T. Flotte, B. Carter, 2001 .

Adeno-associated viruses as gene transfer vehicles.

B. Carter, 2000, Contributions to microbiology.

Repeated Delivery of Adeno-Associated Virus Vectors to the Rabbit Airway

T. Flotte, F. Askin, W. Guggino, 1999, Journal of Virology.

Physical map and strand polarity of specific fragments of adenovirus-associated virus DNA produced by endonuclease R-EcoRI

G. Khoury, B. Carter, D. Denhardt, 1975, Journal of virology.

Mutagenesis of an AUG codon in the adeno-associated virus rep gene: effects on viral DNA replication.

B. Carter, N. Chejanovsky, Nor Chejanovsky, 1989, Virology.

A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease.

R. Gibson, T. Reynolds, D. Waltz, 2001, Human gene therapy.

A lambda library of Herpes simplex virus type 1 (KOS) DNA fragments obtained by partial digestion with Sau3A.

L. Enquist, B. Carter, A. Colberg-Poley, 1983, Gene.

Adeno-Associated Virus Defectiveness and the Nature of the Adenovirus Helper Function

B. Carter, C. Laughlin, 1984 .

Review Adeno-Associated Virus Vectors in Clinical Trials

B. Carter, 2005 .

Safety and Biological Efficacy of an Adeno‐Associated Virus Vector–Cystic Fibrosis Transmembrane Regulator (AAV‐CFTR) in the Cystic Fibrosis Maxillary Sinus

T. Flotte, A. Norbash, J. Wine, 1999, The Laryngoscope.

Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung.

T. Flotte, T. Reynolds, F. Askin, 1996, Gene therapy.

In vivo model of adeno-associated virus vector persistence and rescue

T. Flotte, T. Reynolds, G. Cutting, 1996, Journal of virology.

An improved system for packaging recombinant adeno-associated virus vectors capable of in vivo transduction.

T. Flotte, W. Guggino, S. Afione, 1995, Gene therapy.

Alternate mRNA splicing is required for synthesis of adeno-associated virus VP1 capsid protein

J. Trempe, B. Carter, 1988, Journal of virology.

Properties of an adenovirus type 2 mutant, Ad2dl807, having a deletion near the right-hand genome terminus: failure to help AAV replication.

B. Carter, C. Laughlin, G. Ketner, 1983, Virology.

AAV Infection: Protection from Cancer.

A. Srivastava, B. Carter, A. Srivastava, 2017, Human gene therapy.

The promise of adeno-associated virus vectors

B. Carter, 1996, Nature Biotechnology.

AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice.

R. Desnick, James M. Wilson, Seng H. Cheng, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

adeno-associated virus (AAV) Rep proteins on Interaction of wild-type and mutant

M. Weitzman, B. Carter, R. Owens, 2013 .

Interaction of wild-type and mutant adeno-associated virus (AAV) Rep proteins on AAV hairpin DNA

M. Weitzman, B. Carter, R. Owens, 1996, Journal of virology.

Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy.

T. Flotte, E. Schwiebert, W. Guggino, 2005, Human gene therapy.

Adeno-associated virus RNA transcription in vivo.

B. Carter, C. Laughlin, C. J. Marcus, 1981, European journal of biochemistry.

Replication of a human parvovirus nonsense mutant in mammalian cells containing an inducible amber suppressor.

B. Carter, N. Chejanovsky, 1989, Virology.

Gene expression in adeno-associated virus vectors: the effects of chimeric mRNA structure, helper virus, and adenovirus VA1 RNA.

J. Trempe, J. Tratschin, B. Carter, 1987, Virology.

Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice

S. Bunting, S. Fong, B. Carter, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Genome localization of simian virus 40 RNA species

P. Howley, M. Martin, G. Khoury, 1976, Journal of virology.

Identification of a DNA-binding domain in the amino terminus of adeno-associated virus Rep proteins

M. Weitzman, B. Carter, R. Owens, 1993, Journal of virology.

Clinical development with adeno-associated virus vectors

B. Carter, 2005 .

Adeno-associated virus rep proteins produced in insect and mammalian expression systems: wild-type and dominant-negative mutant proteins bind to the viral replication origin.

J. Trempe, B. Carter, N. Chejanovsky, 1991, Virology.

Effect of deletions in adenovirus early region 1 genes upon replication of adeno-associated virus

N. Jones, B. Carter, C. Laughlin, 1982, Journal of virology.

Specific cleavage of adenovirus-associated virus DNA by restriction endonuclease R-EcoRI--characterization of cleavage products.

G. Khoury, B. Carter, 1975, Virology.

Effect of adeno-associated virus on transformation of NIH 3T3 cells by ras gene and on tumorigenicity of an NIH 3T3 transformed cell line.

B. Carter, E. Katz, 1986, Cancer research.

Variant and Defective Interfering Parvoviruses

B. Carter, 1984 .

Defective-interfering particles of the human parvovirus adeno-associated virus.

B. Carter, C. Laughlin, D. Risin, 1979, Virology.

Adeno-associated virus autointerference.

B. Carter, C. Laughlin, L. M. de la Maza, 1979, Virology.

Strategy to detect pre-existing immunity to AAV gene therapy

S. Fong, B. Carter, L. Tsuruda, 2017, Gene Therapy.

Suppressing Nonsense for Gene Therapy.

B. Carter, 2022, Human gene therapy.

In vitro resolution of adeno-associated virus DNA hairpin termini by wild-type Rep protein is inhibited by a dominant-negative mutant of rep

B. Carter, R. Owens, 1992, Journal of virology.

Identification of the trans-acting Rep proteins of adeno-associated virus by antibodies to a synthetic oligopeptide

J. Trempe, B. Carter, E. Mendelson, 1986, Journal of virology.

Adeno-associated virus rep protein synthesis during productive infection

B. Carter, E. Mendelson, E. Mendelson, 1989, Journal of virology.

My Pathway to Adeno-Associated Virus and Adeno-Associated Virus Gene Therapy: A Personal Perspective

B. Carter, 2020, Human gene therapy.

Negative and positive regulation in trans of gene expression from adeno-associated virus vectors in mammalian cells by a viral rep gene product

J. Tratschin, B. Carter, J. Tal, 1986, Molecular and cellular biology.

Gene Therapy and Viruses

D. Kohn, J. Glorioso, B. Carter, 2009 .

Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi

Brian L. Gilmore, S. Harper, B. Davidson, 2008, Proceedings of the National Academy of Sciences.

Intracellular pools of bacteriophage λ deoxyribonucleic acid

B. Carter, M. G. Smith, 1970 .

Cloning of the human thyrotropin beta-subunit gene and transient expression of biologically active human thyrotropin after gene transfection.

J. Trempe, S. Radovick, B. Carter, 1988, Molecular endocrinology.

Effect of gene therapy on visual function in Leber's congenital amaurosis.

Nick Tyler, Fred W Fitzke, Gary S Rubin, 2008, The New England journal of medicine.

Multiple structures of adeno-associated virus DNA: analysis of terminally labeled molecules with endonuclease R-Hae III

S. Eisenberg, B. Carter, D. Denhardt, 1976, Journal of virology.

Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function

J. Tratschin, B. Carter, I. L. Miller, 1984, Journal of virology.

Adeno-associated Virus and AAV Vectors for Gene Delivery

B. Carter, R. Peluso, H. Burstein, 2003 .

Concepts in genetic medicine

B. Carter, B. Dropulić, 2008 .

Adeno-associated virus vector for high-frequency integration, expression, and rescue of genes in mammalian cells

J. Tratschin, B. Carter, M. G. Smith, 1985, Molecular and cellular biology.

Adenovirus helper function for growth of adeno-associated virus: effect of temperature-sensitive mutations in adenovirus early gene region 2

B. Carter, C. Laughlin, F T Jay, 1980, Journal of virology.

Adenovirus containing a deletion of the early region 2A gene allows growth of adeno-associated virus with decreased efficiency.

D. Klessig, B. Carter, B. Antoni, 1992, Virology.

Characterization of adeno-associated virus rep proteins in human cells by antibodies raised against rep expressed in Escherichia coli.

J. Trempe, B. Carter, E. Mendelson, 1987, Virology.

A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase

J. Tratschin, B. Carter, M. H. West, 1984, Molecular and cellular biology.

Cloning of infectious adeno-associated virus genomes in bacterial plasmids.

J. Tratschin, B. Carter, C. Laughlin, 1983, Gene.

Heavy and Light Particles of Adeno-Associated Virus

B. Carter, L. M. de la Maza, 1980, Journal of Virology.

Replication of adeno-associated virus type 2 in human lymphocytic cells and interaction with HIV-1.

G. Rechavi, B. Carter, F. Mileguir, 1992, Virology.

Molecular structure of adeno-associated virus variant DNA.

B. Carter, L. M. de la Maza, L. M. D. L. Maza, 1980, The Journal of biological chemistry.

Gene expression from adeno-associated virus vectors in airway epithelial cells.

T. Flotte, S. Afione, B. Carter, 1992, American journal of respiratory cell and molecular biology.

Chromatin-like structure of adeno-associated virus DNA in infected cells

B. Carter, C. Marcus-Sekura, 1983, Journal of virology.

Adeno-associated virus DNA structure. Restriction endonuclease maps and arrangement of terminal sequences.

B. Carter, L. M. de la Maza, 1977, Virology.

Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial.

Thomas Ferkol, Carlos Milla, Frank Accurso, 2007, Human gene therapy.

Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study.

Terence R Flotte, Suzanne Beck, T. Flotte, 2003, Human gene therapy.

A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies.

Terence R Flotte, Phyllis Gardner, T. Flotte, 2002, Human gene therapy.

Charting a clear path: the ASGCT Standardized Pathways Conference.

David A. Williams, F. Bushman, T. Flotte, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

CLINICAL DEVELOPMENT OF AAV VECTORS

B. Carter, 2010 .

Adeno-associated virus vectors in clinical trials.

B. Carter, Barrie J Carter, 2005, Human gene therapy.

A Phase I/II Study of tgAAV-CF for the Treatment of Chronic Sinusitis in Patients with Cystic Fibrosis. Stanford University, Stanford, California

T. Flotte, T. Reynolds, J. Wine, 1998 .

A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis.

T. Flotte, T. Reynolds, J. Wine, 1998, Human gene therapy.

Self-complementarity of terminal sequences within plus or minus strands of adenovirus-associated virus DNA.

B. Carter, C. Garon, J. Rose, 1973, Proceedings of the National Academy of Sciences of the United States of America.

Nonclinical toxicology in support of licensure of gene therapies. Arlington, VA, USA, March 13-14, 2003.

R. Frederickson, B. Carter, A. Pilaro, 2003, Molecular Therapy.

18. Viral Vectors for Gene Therapy

B. Carter, 2008 .

A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease.

T. Flotte, T. Reynolds, R. Wetzel, 1996, Human gene therapy.

Genome localization of adeno-associated virus RNA

K. Berns, B. Carter, K. Fife, 1976, Journal of virology.

Two stages in the replication of bacteriophage λ DNA

B. Carter, M. G. Smith, B. Shaw, 1969 .

Separate helper functions provided by adenovirus for adenovirus-associated virus multiplication.

B. Carter, R. Dolin, J. Garrison, 1973, Nature: New biology.

Adenovirus-Associated Virus Multiplication IX. Extent of Transcription of the Viral Genome In Vivo

G. Khoury, B. Carter, J. Rose, 1972, Journal of virology.

Adenovirus-Associated Virus Multiplication VIII. Analysis of In Vivo Transcription Induced by Complete or Partial Helper Viruses

B. Carter, J. Rose, 1972, Journal of virology.

Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.

I. Martins, B. Davidson, J. McBride, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Redox modifier genes and pathways in amyotrophic lateral sclerosis.

J. Engelhardt, B. Carter, Stephanie Choi, 2009, Antioxidants & redox signaling.

Assembly of adeno-associated virus.

B. Carter, M. Myers, 1980, Virology.

Cleavage of adeno-associated virus DNA with Sali,Psti and Haeii restriction endonucleases.

B. Carter, L. M. Maza, 1976, Nucleic Acids Research.

Transcription in vivo of a defective parvovirus: sedimentation and electrophoretic analysis of RNA synthesized by adenovirus-associated virus and its helper adenovirus.

B. Carter, J. Rose, 1974, Virology.

Defective regulation of outwardly rectifying Cl− channels by protein kinase A corrected by insertion of CFTR

T. Flotte, W. Guggino, P. Zeitlin, 1992, Nature.

Inhibition of adenovirus oncogenicity in hamsters by adeno-associated virus DNA.

B. Carter, L. M. de la Maza, 1981, Journal of the National Cancer Institute.

Effect of a viral rep gene on transformation of cells by an adeno-associated virus vector.

B. Carter, M. G. Smith, E. Mendelson, 1988, Virology.

Adeno-associated virus vectors

B. Carter, Barrie J. Carter, 1992, Current Biology.

Eukaryotic translational control: adeno-associated virus protein synthesis is affected by a mutation in the adenovirus DNA-binding protein.

B. Carter, C. Laughlin, F. Jay, 1981, Proceedings of the National Academy of Sciences of the United States of America.

In vivo gene therapy with adeno-associated virus vectors for cystic fibrosis.

T. Flotte, B. Carter, 1997, Advances in pharmacology.

Adeno-associated viruses having nonsense mutations in the capsid genes: growth in mammalian cells containing an inducible amber suppressor.

B. Carter, J. Smuda, 1991, Virology.

Molecular cloning of adeno-associated virus variant genomes and generation of infectious virus by recombination in mammalian cells.

P. Senapathy, B. Carter, 1984, The Journal of biological chemistry.

Development of adeno-associated virus vectors for gene therapy of cystic fibrosis.

T. Flotte, B. Carter, 1996, Current topics in microbiology and immunology.

Analysis ofParvovirus mRNA bySedimentation and Electrophoresis inAqueous andNonaqueous Solution

B. Carter, 1974 .

Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter.

M. Drumm, T. Flotte, W. Guggino, 1993, The Journal of biological chemistry.

Authors' Response to Jesse D. Riordan, Hum Gene Ther 2017;28:375-376; DOI: 10.1089/hum.2017.045.

A. Srivastava, B. Carter, A. Srivastava, 2017, Human gene therapy.

A prescription for gene therapy: The first cabo gene therapy working group

E. B. Butler, S. Scherer, J. Nemunaitis, 2000 .

Replication of adeno-associated virus DNA. Complementation of naturally occurring rep- mutants by a wild-type genome or an ori- mutant and correction of terminal palindrome deletions.

P. Senapathy, J. Tratschin, B. Carter, 1984, Journal of molecular biology.

Clinical Trial of Gene Therapy for Early Onset Severe Retinal Dystrophy Caused by Defects in RPE65

G. Rubin, A. Stockman, S. Bhattacharya, 2008 .

Adeno-associated virus DNA replication complexes in herpes simplex virus or adenovirus-infected cells.

H. Handa, B. Carter, 1979, The Journal of biological chemistry.

Adeno-associated virus vectors for gene therapy of cystic fibrosis.

T. Flotte, B. Carter, Terence R. Flotte, 1998, Methods in enzymology.

Gene therapy as drug development.

B. Carter, 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

Spliced adenovirus-associated virus RNA.

H. Westphal, B. Carter, C. Laughlin, 1979, Proceedings of the National Academy of Sciences of the United States of America.

Analysis of two potential shuttle vectors containing herpes simplex virus defective DNA.

D. Court, L. Enquist, S. E. Bear, 1984, Journal of molecular and applied genetics.

Intracellular distribution and polyadenylate content of adeno-associated virus RNA sequences.

B. Carter, 1976, Virology.

Redox modifier genes and pathways in amyotrophic lateral sclerosis.

J. Engelhardt, B. Carter, Stephanie Choi, 2009, Antioxidants & redox signaling.

Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi

Brian L. Gilmore, S. Harper, B. Davidson, 2008, Proceedings of the National Academy of Sciences.

A mutant cell line derived from NIH/3T3 cells: two oncogenes required for in vitro transformation.

B. Carter, E. Katz, 1986, Journal of the National Cancer Institute.

Adeno-associated virus replication. The effect of L-canavanine or a helper virus mutation on accumulation of viral capsids and progeny single-stranded DNA.

B. Carter, M. Myers, 1981, The Journal of biological chemistry.